Orforglipron
Oral small-molecule GLP-1 agonist. Orforglipron is FDA approved (Foundayo, Apr 2026); research-chemical versions are not the approved drug.
Key facts
- Class
- Oral small-molecule GLP-1 agonist
- Not a peptide
- Also called
- Foundayo, orfo
- Half-life
- approximately 29 to 49 hours
- oral, in people · FDA label (Foundayo)
- FDA status
- Approved (Foundayo, Apr 2026)
- 1 Apr 2026
- WADA
- Not listed
- 2026 Prohibited List
Orforglipron guides
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Weight loss | 55 | 0 | 9 | Human RCT evidence, 4 of 4Lancet 2026, PMID 41275875 |
| Diabetes | Not in our ledger | Not in our ledger | 6 | Human RCT evidence, 4 of 4Lancet 2026, PMID 41275875 |
| Heart health | Not in our ledger | Not in our ledger | 2 | Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40960239 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
A small molecule, not a peptide, that acts on the GLP-1 receptor
Its phase 1 paper describes orforglipron as an oral non-peptide GLP-1 receptor agonist, so it is a small molecule taken by mouth, not a peptide.[8]
The label gives an elimination half-life of approximately 29 to 49 hours after an oral dose.[5]
A disposition study measured a mean absolute oral bioavailability of 79.1%.[9]
Approved in the US, listed in the UK, no Health Canada record
FDA has approved orforglipron as a tablet; the Drugs@FDA record shows the brand Foundayo and an original approval date of 20260401.[3]
The UK emc lists it under the same brand name.[10]
Health Canada's product database search returned no orforglipron record.[11]
The label carries a boxed warning for thyroid C-cell tumors, the warning given for products with GLP-1 receptor agonist activity.[5]
Strongest finding and open question
In the 72-week phase 3 obesity trial, the top dose gave a mean weight change of -11.2%.[7]
In a maintenance trial, participants who reached a weight plateau after tirzepatide kept an estimated 74.7% of their weight reduction on orforglipron against 49.2% on placebo.[12]
Tolerability is the open question: adverse events led to treatment discontinuation in 5.3 to 10.3% on orforglipron against 2.7% on placebo.[7]
Compared with
Common questions
Is Orforglipron FDA approved?
Orforglipron is FDA approved (Foundayo, Apr 2026). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
Is Orforglipron a peptide?
No. It is a oral small-molecule glp-1 agonist. It is listed here because people research it alongside peptides.
What is orforglipron?
An oral, non-peptide GLP-1 receptor agonist.[8]
Are there orforglipron pills?
Yes, orforglipron is approved as a tablet: the FDA record lists the dosage form as TABLET.[3]
How does orforglipron work?
It acts as a GLP-1 receptor agonist; its label carries a boxed warning for thyroid C-cell tumors that applies to products with that activity.[5]
What are the orforglipron clinical trials?
The largest phase 3 obesity trial ran 72 weeks and reported a mean body-weight change of -11.2% at the top dose.[7]
Where is the orforglipron (Foundayo) FDA label?
Drugs@FDA lists Foundayo under New Drug Application 220934, and the full prescribing information is the DailyMed label linked in this page's sources.[13]
Sources
- 1FDA approves first new molecular entity under National Priority Voucher program (Foundayo, orforglipron), 1 Apr 2026U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3United States: Approved by FDA as Foundayo (orforglipron), Eli Lilly, 1 April 2026, for chronic weight management in adults (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 4Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 5These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
- 7Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 8Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
- 9Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.Clinical pharmacology in drug development · 2026PMID 40888509Accessed 2 Oct 2026
- 10emc (UK) search: orforglipronElectronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
- 11Health Canada Drug Product Database search: ingredient name "orforglipron"Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 12Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
- 13Official web pageOfficial web page · web page
Found an error? Report a correction.